Tag:
Inviragen
Latest Headlines
Latest Headlines
Hand, foot and mouth vaccine triggers 100% immune response
Hand, foot and mouth is a viral infection caused by a number of viruses, including the human enterovirus 71. Generally, it's just thought of as a mild infection that every now and then sweeps child care facilities and kindergartens, but it can be more sinister, and Inviragen has released some topline data from a Phase I trial showing an immune response from everyone receiving the vaccine.
Inviragen, U of Texas land $3M grant for chikungunya vaccine
With the help of a four-year, $3 million grant from the National Institute of Allergy and Infectious Diseases, Inviragen and the University of Texas Medical Branch (UTMB) are furthering development
Inviragen forms dengue partnership with IVI
Vaccine maker Inviragen has signed a memorandum of understanding with the nonprofit International Vaccine Institute (IVI) for further development of dengue vaccines. Currently, Inviragen has a
Inviragen starts Colombian Phase I dengue trial
Inviragen and the Program for the Study and Control of Tropical Diseases have announced a Phase I trial in Colombia of Inviragen's lead vaccine candidate, DENVax. The vaccine should protect against
Inviragen, PharmaJet land $15.5M for needle-free dengue vax
The National Institute of Allergy and Infectious Diseases awarded a five-year, $15.5 million contract to Inviragen and PharmaJet to continue their work on a needle-free dengue vaccine. The disease,
Vax developers merge, land $15M venture round
Fort Collins, CO-based Inviragen is merging with Singapore's SingVax in a deal that will bring together to vaccine developers focused on advancing new shots to prevent infectious diseases in
